Pioglitazone-induced congestive heart failure and pulmonary edema in a patient with preserved ejection fraction
Authors:
Open Access
- 1 March 2016
- journal article
- case report
- Published by SAGE Publications in Journal of Pharmacology and Pharmacotherapeutics
- Vol. 7 (1) , 41-43
Abstract
Pioglitazone-induced heart failure is known in patients with underlying heart disease, but is not well documented in patients with normal left ventricular function. Pioglitazone has been very popular as it is an insulin sensitizer and insulin resistance is prevalent among Indians. Fluid retention exacerbates pre-existing heart failure or precipitates heart failure in a patient with underlying left ventricular dysfunction. However, pathogenesis of heart failure in a patient with normal left ventricular function is not known. Probably it is due to dose-related effect on pulmonary endothelial permeability, rather than alterations in left ventricular mass or ejection fraction. We report a patient who developed congestive heart failure and pulmonary edema with normal left ventricular function within 1 year of starting pioglitazone therapy. We have to be careful in monitoring all possible side effects during followup when patients are on pioglitazone therapy.Keywords
This publication has 9 references indexed in Scilit:
- The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesBMC Cardiovascular Disorders, 2014
- Usage of pioglitazone at Medanta, the MedicityIndian Journal of Endocrinology and Metabolism, 2014
- Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013Diabetes Care, 2013
- Pioglitazone: Indian perspectiveIndian Journal of Endocrinology and Metabolism, 2011
- Delayed onset of rosiglitazone-induced pulmonary oedemaEuropean Journal of Internal Medicine, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- Pioglitazone-induced heart failure despite normal left ventricular functionThe American Journal of Medicine, 2004
- Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureCirculation, 2003
- A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2002